You Can’t Stop Seattle – that is the message Delta is sending with the launch of an ad campaign targeting Delta’s growing West Coast hub. http://news.delta.com/you-can-t-stop-delta-seattle-launch-ad-campaign

LabCorp Announces the Launch of the Epi proColon® Test for Colorectal Cancer Screening First FDA-Approved Blood-Based Colorectal Cancer Test Offers Alternative for Patients Non-Compliant with Existing […]

IMS Health Holdings, Inc. (NYSE:IMS) and Quintiles Transnational Holdings Inc. (NYSE:Q) announced today that their respective boards of directors approved a definitive merger agreement, pursuant to […]

Epigenomics AG: China FDA names Epigenomics’ blood-based Septin9 colorectal cancer test a most innovative medical product for 2015 Berlin (Germany) and Germantown, MD (U.S.A.), May 2, […]

From LABIOTECH.EU http://labiotech.eu/epigenomics-epiprocolon-interview-blood-test-cancer-colon-diagnostics-us/ We met the Biotech that just launched the First & Only Blood Test for Colorectal Cancer in the US 14/04/2016 Colorectal cancer is […]

Apr. 13, 2016 2:19 PM ET In pulling off the almost unheard-of feat of successfully appealing against an FDA rejection, Epigenomics (OTCQX:EPGNF) today got full approval […]

12-April-2016 Curetis AG / Curetis Publishes Full-Year 2015 Financial Results and Introduces 2016 Guidance . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is […]

http://www.japantimes.co.jp/news/2016/04/12/national/science-health/massive-whole-genome-study-finds-six-types-of-liver-cancer/#.Vw5qsJMrIUE

BioChain Acquires China Rights To Epigenomics AG Lung Cancer IVD [4/6/2016] BioChain, a US-China diagnostics/genomics tools company, has in-licensed China rights to a novel blood-based lung […]